Study Data Presented at TVT on the Economics of Minimalist TAVR, PARTNER 3 Bicuspid TAVR
The 3M-TAVR study demonstrated positive findings supporting similar clinical outcomes and substantial cost savings associated with minimalist TAVR when compared with conventional TAVR in patients at intermediate risk for surgery.
- The 3M-TAVR study demonstrated positive findings supporting similar clinical outcomes and substantial cost savings associated with minimalist TAVR when compared with conventional TAVR in patients at intermediate risk for surgery.
- Cumulative cost differences out to 30 days post procedure were $11,305 lower in the 3M cohort compared to traditional TAVR.
- "These data continue to build on the PARTNER 3 trial that demonstrated SAPIEN 3 TAVR to be superior to surgery for low-risk surgical patients."
- Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3,SAPIEN and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation.